Kidney Biopsy Market

• Rising incidence of cancer is driving the market growth

Kidney cancer can strike individuals of any age. Kidney cancer has a wide range of signs and symptoms, but they can be difficult to distinguish from other, more common medical problems since they are non-specific. In its early stages, kidney cancer typically exhibits neither signs nor symptoms. Over time, signs and symptoms could include blood in the urine, which could be pink, red, or cola-colored; persistent back or side pain; loss of appetite; unexplained weight loss; exhaustion; and fever. Adults are most likely to develop kidney cancer than any other cancer form.

An aggressive kidney cancer known as a Wilms tumor is more common in young children. The 14th most prevalent cancer in the world is renal cancer, also known as kidney cancer or renal cell adenocarcinoma. It ranks 14th among females and ninth among men. The number of kidney cancer diagnoses increased to around 30,000 in 2020. Kidney cancer cases are on the rise worldwide and are becoming a serious socioeconomic problem as a result of multiple risk factors like smoking, obesity, high blood pressure (hypertension), or a family history of the disease.

In light of this, the growing number of kidney cancer patients is driving growth in the worldwide kidney biopsy market CAGR by increasing demand for renal biopsy.

The growth and development of the kidney biopsy market have been greatly influenced by improvements in biopsy methods. These developments have enhanced the safety, accuracy, and patient experience of the biopsy technique. The market for biopsy devices is being shaped by robotically assisted systems, which also assist in preventing post-biopsy problems. Medical authorities have been approving the equipment to make the process simpler. Robot-assisted biopsy is done to boost the precision and accuracy of the biopsy process. Moreover, image-guided kidney biopsies, such as those performed using ultrasonography or computed tomography, are now more common.

These procedures provide accurate collection and reduce the chance of problems by using real-time imaging to guide the needle exactly to the targeted kidney location. Thus, driving the kidney biopsy market revenue.

The Global Kidney Biopsy Market Industry is expected to experience substantial growth over the coming years. Projections indicate that the market will reach 2.31 USD Billion in 2024 and further expand to 3.78 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate (CAGR) of 4.59% from 2025 to 2035, suggesting a robust demand for kidney biopsy procedures. Factors contributing to this growth include the increasing prevalence of kidney diseases, advancements in biopsy techniques, and heightened awareness of kidney health. These dynamics collectively indicate a promising future for the kidney biopsy market.

The aging population worldwide is a significant factor propelling the Global Kidney Biopsy Market Industry. As individuals age, the risk of developing kidney-related ailments increases, necessitating more frequent diagnostic evaluations. The United Nations projects that the global population aged 65 and older will reach 1.5 billion by 2050, highlighting the urgent need for effective kidney disease management strategies. This demographic shift is likely to result in a higher demand for kidney biopsies, as healthcare providers seek to accurately diagnose and treat age-related kidney conditions. Consequently, the market is poised for growth, driven by the increasing healthcare needs of the elderly.

Improved reimbursement policies for kidney biopsy procedures are positively impacting the Global Kidney Biopsy Market Industry. Many healthcare systems are recognizing the necessity of kidney biopsies for accurate diagnosis and treatment planning, leading to more favorable reimbursement rates. This shift encourages healthcare providers to perform biopsies more frequently, as financial barriers are reduced. As reimbursement frameworks evolve, the accessibility of kidney biopsies is likely to improve, fostering market growth. The anticipated increase in procedures aligns with the overall market expansion, as stakeholders adapt to changing healthcare policies that support kidney disease diagnostics.

Increased awareness regarding kidney health and the importance of early detection is driving the Global Kidney Biopsy Market Industry. Public health initiatives and screening programs aimed at identifying individuals at risk of kidney diseases have gained momentum. These programs often emphasize the need for kidney biopsies as a vital diagnostic tool. As more individuals undergo screening, the demand for kidney biopsies is likely to rise, contributing to market growth. This heightened awareness aligns with the projected compound annual growth rate (CAGR) of 4.59% from 2025 to 2035, reflecting a sustained interest in proactive kidney health management.

The rising incidence of kidney diseases globally is a primary driver for the Global Kidney Biopsy Market Industry. Chronic kidney disease (CKD) affects millions worldwide, with the World Health Organization reporting that approximately 10% of the global population suffers from some form of kidney impairment. This growing patient population necessitates accurate diagnostic methods, including kidney biopsies, to assess the extent of kidney damage and guide treatment options. As the demand for kidney biopsies increases, the market is projected to reach 2.31 USD Billion in 2024, indicating a robust growth trajectory fueled by the urgent need for effective kidney disease management.

Innovations in biopsy techniques are significantly influencing the Global Kidney Biopsy Market Industry. The introduction of minimally invasive procedures, such as ultrasound-guided biopsies, enhances patient safety and comfort while improving diagnostic accuracy. These advancements reduce complications and recovery times, making kidney biopsies more appealing to both patients and healthcare providers. As technology continues to evolve, the market is expected to expand, with projections indicating a growth to 3.78 USD Billion by 2035. This trend suggests that ongoing research and development in biopsy methodologies will play a crucial role in shaping the future landscape of kidney diagnostics.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American kidney biopsy market area will dominate this market. The high costs of healthcare, government funding of R&D, widespread use of technologically advanced medical devices for kidney disease diagnosis and treatment, an increase in the number of kidney disease patients, diabetes, and other risk factors for renal failure, as well as the high spending on health care, are all factors driving the growth of the regional market.

The number of patients with diabetes, kidney disease, and other risk factors for renal failure is rising, which is also driving the market. Expanding usage of new technologies for treating ailments, favorable reimbursement rules, and significant investments in their development will propel market growth.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  KIDNEY BIOPSY MARKET SHARE BY REGION 2023 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe kidney biopsy market accounts for the second-largest market share. The growth of the regional market is attributed to the availability of research funding, rising government support for R&D, increasing emphasis on the development of cutting-edge diagnostic tools in urology, and an increase in the number of specialty services offered by various healthcare providers. Additionally, it is anticipated that increased applications, sizable expenditures, and favorable reimbursement rules will all improve the performance of the regional market.

Further, the German kidney biopsy market held the largest market share, and the UK kidney biopsy market was the fastest growing market in the European region

The Asia-Pacific Kidney biopsy Market is expected to grow at the fastest CAGR from 2024 to 2032 due to the rising prevalence of diabetes and the rise in kidney transplant surgeries performed in urology clinics. The market is also fueled by increased healthcare spending and the quickly expanding healthcare technology sector. Additionally, growing demand for high-quality medical devices is probably going to result in higher use of cutting-edge technology, speeding up market expansion in this sector.

Moreover, China’s kidney biopsy market held the largest market share, and the Indian kidney biopsy market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the kidney biopsy market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, kidney biopsy industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  kidney biopsy industry to benefit clients and increase the market sector. In recent years, the kidney biopsy industry has offered some of the most significant advantages to market.

Major players in the kidney biopsy market attempting to increase market demand by investing in research and development operations include Boston Scientific Corporation (U.S.), Cook Medical (U.S.), C R Bard, Inc. (U.S.), Devicor Medical Products Inc. (U.S.), Hologic Inc. (U.S.), Intact Medical Corporation (U.S.), Precision Biopsy, LLC (U.S.), Scion Medical Technologies LLC (U.S.), Integra LifeSciences Corporation (U.S.), Creganna (U.S.), Focal Therapeutics, Inc. (U.S.), CareFusion (U.S.), Argon Medical Devices, Inc. (U.S.) and others.

With its headquarters in Plano, Texas, Argon Medical is a maker of speciality medical goods on a  scale. Vascular surgery, interventional cardiology, interventional radiology, and oncology all have a variety of medical equipment available from Argon. The Argon brand is known for top-of-the-line solutions that enhance patient outcomes through percutaneous, image-guided operations. Argon supports its international customers through a direct sales organisation and through enduring connections with OEMs, strategic partners, and medical device distributors by utilizing a well-established sales and marketing infrastructure.

Over 1000 people work at Argon worldwide in manufacturing facilities in Athens, Texas, Wheeling, Illinois, Rochester, New York, and Portage, Wisconsin.

Cook Medical Inc., a division of Cook Group Inc., is a manufacturer, distributor, and developer of medical devices for minimally invasive procedures. Catheters, grafts, stents, plugs, wire guides, needles, balloons, feeding tubes, and extractors are among the main items produced by the company. Among other specialties, it provides goods and services in anesthesiology, bariatrics, cardiothoracic, general, gynecologic oncology, gynecology, neurosurgery, colorectal, endovascular, peripheral cardiology, plastic surgery, traumatology, urogynecology, and urology.